Comparison of 25 and 75 mg/day naftopidil for lower urinary tract symptoms associated with benign prostatic hyperplasia: A prospective, randomized controlled study

Teruhiko Yokoyama, Hiromi Kumon, Yoshitsugu Nasu, Hitoshi Takamoto, Toyohiko Watanabe

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Background: The present study investigated the efficacy, safety, and utility of starting an α 1d-selective antagonist, naftopidil, at 75 or 25 mg/day in patients with lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH). Methods: In this prospective comparative study, the subjects comprised 153 patients with LUTS associated with BPH. Patients were randomized to receive either 25 mg/day (Group LD) or 75 mg/day (Group HD) of naftopidil for 4 weeks. The lower urinary tract disease symptom score (LUTDSS), the International Prostate Symptom Score (IPSS), the Quality of life assessment index, the maximum flow rate (Q max), and the residual urine volume were compared between the groups. Results: In both groups, the LUTDSS and the IPSS were significantly improved at the endpoint and no significant intergroup differences were identified. However, the improvement in the Q max was significantly better for Group HD than for Group LD. The overall efficacy did not differ significantly between the groups. The degree of improvement in voiding symptoms and LUTDSS among patients with moderate symptoms was significantly greater for Group HD than for Group LD. The frequency of adverse reactions did not differ significantly between the groups. Conclusions: Starting administration at 75 mg/day rather than 25mg/day is helpful for LUTS associated with BPH for patients with moderate symptoms, particularly in improving voiding symptoms. The 75 mg/day administration was considered to be a recommendable therapeutic dose in some patients.

Original languageEnglish
Pages (from-to)932-938
Number of pages7
JournalInternational Journal of Urology
Volume13
Issue number7
DOIs
Publication statusPublished - Jul 2006
Externally publishedYes

Fingerprint

Lower Urinary Tract Symptoms
Prostatic Hyperplasia
Urologic Diseases
Prostate
Residual Volume
naftopidil
Quality of Life
Urine
Prospective Studies
Safety

Keywords

  • Benign prostatic hyperplasia
  • Lower urinary tract symptoms
  • Naftopidil
  • Optimal dose

ASJC Scopus subject areas

  • Urology

Cite this

Comparison of 25 and 75 mg/day naftopidil for lower urinary tract symptoms associated with benign prostatic hyperplasia : A prospective, randomized controlled study. / Yokoyama, Teruhiko; Kumon, Hiromi; Nasu, Yoshitsugu; Takamoto, Hitoshi; Watanabe, Toyohiko.

In: International Journal of Urology, Vol. 13, No. 7, 07.2006, p. 932-938.

Research output: Contribution to journalArticle

@article{79abe7e71c474f61bc0d4600b624633f,
title = "Comparison of 25 and 75 mg/day naftopidil for lower urinary tract symptoms associated with benign prostatic hyperplasia: A prospective, randomized controlled study",
abstract = "Background: The present study investigated the efficacy, safety, and utility of starting an α 1d-selective antagonist, naftopidil, at 75 or 25 mg/day in patients with lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH). Methods: In this prospective comparative study, the subjects comprised 153 patients with LUTS associated with BPH. Patients were randomized to receive either 25 mg/day (Group LD) or 75 mg/day (Group HD) of naftopidil for 4 weeks. The lower urinary tract disease symptom score (LUTDSS), the International Prostate Symptom Score (IPSS), the Quality of life assessment index, the maximum flow rate (Q max), and the residual urine volume were compared between the groups. Results: In both groups, the LUTDSS and the IPSS were significantly improved at the endpoint and no significant intergroup differences were identified. However, the improvement in the Q max was significantly better for Group HD than for Group LD. The overall efficacy did not differ significantly between the groups. The degree of improvement in voiding symptoms and LUTDSS among patients with moderate symptoms was significantly greater for Group HD than for Group LD. The frequency of adverse reactions did not differ significantly between the groups. Conclusions: Starting administration at 75 mg/day rather than 25mg/day is helpful for LUTS associated with BPH for patients with moderate symptoms, particularly in improving voiding symptoms. The 75 mg/day administration was considered to be a recommendable therapeutic dose in some patients.",
keywords = "Benign prostatic hyperplasia, Lower urinary tract symptoms, Naftopidil, Optimal dose",
author = "Teruhiko Yokoyama and Hiromi Kumon and Yoshitsugu Nasu and Hitoshi Takamoto and Toyohiko Watanabe",
year = "2006",
month = "7",
doi = "10.1111/j.1442-2042.2006.01443.x",
language = "English",
volume = "13",
pages = "932--938",
journal = "International Journal of Urology",
issn = "0919-8172",
publisher = "Wiley-Blackwell",
number = "7",

}

TY - JOUR

T1 - Comparison of 25 and 75 mg/day naftopidil for lower urinary tract symptoms associated with benign prostatic hyperplasia

T2 - A prospective, randomized controlled study

AU - Yokoyama, Teruhiko

AU - Kumon, Hiromi

AU - Nasu, Yoshitsugu

AU - Takamoto, Hitoshi

AU - Watanabe, Toyohiko

PY - 2006/7

Y1 - 2006/7

N2 - Background: The present study investigated the efficacy, safety, and utility of starting an α 1d-selective antagonist, naftopidil, at 75 or 25 mg/day in patients with lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH). Methods: In this prospective comparative study, the subjects comprised 153 patients with LUTS associated with BPH. Patients were randomized to receive either 25 mg/day (Group LD) or 75 mg/day (Group HD) of naftopidil for 4 weeks. The lower urinary tract disease symptom score (LUTDSS), the International Prostate Symptom Score (IPSS), the Quality of life assessment index, the maximum flow rate (Q max), and the residual urine volume were compared between the groups. Results: In both groups, the LUTDSS and the IPSS were significantly improved at the endpoint and no significant intergroup differences were identified. However, the improvement in the Q max was significantly better for Group HD than for Group LD. The overall efficacy did not differ significantly between the groups. The degree of improvement in voiding symptoms and LUTDSS among patients with moderate symptoms was significantly greater for Group HD than for Group LD. The frequency of adverse reactions did not differ significantly between the groups. Conclusions: Starting administration at 75 mg/day rather than 25mg/day is helpful for LUTS associated with BPH for patients with moderate symptoms, particularly in improving voiding symptoms. The 75 mg/day administration was considered to be a recommendable therapeutic dose in some patients.

AB - Background: The present study investigated the efficacy, safety, and utility of starting an α 1d-selective antagonist, naftopidil, at 75 or 25 mg/day in patients with lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH). Methods: In this prospective comparative study, the subjects comprised 153 patients with LUTS associated with BPH. Patients were randomized to receive either 25 mg/day (Group LD) or 75 mg/day (Group HD) of naftopidil for 4 weeks. The lower urinary tract disease symptom score (LUTDSS), the International Prostate Symptom Score (IPSS), the Quality of life assessment index, the maximum flow rate (Q max), and the residual urine volume were compared between the groups. Results: In both groups, the LUTDSS and the IPSS were significantly improved at the endpoint and no significant intergroup differences were identified. However, the improvement in the Q max was significantly better for Group HD than for Group LD. The overall efficacy did not differ significantly between the groups. The degree of improvement in voiding symptoms and LUTDSS among patients with moderate symptoms was significantly greater for Group HD than for Group LD. The frequency of adverse reactions did not differ significantly between the groups. Conclusions: Starting administration at 75 mg/day rather than 25mg/day is helpful for LUTS associated with BPH for patients with moderate symptoms, particularly in improving voiding symptoms. The 75 mg/day administration was considered to be a recommendable therapeutic dose in some patients.

KW - Benign prostatic hyperplasia

KW - Lower urinary tract symptoms

KW - Naftopidil

KW - Optimal dose

UR - http://www.scopus.com/inward/record.url?scp=33745910846&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745910846&partnerID=8YFLogxK

U2 - 10.1111/j.1442-2042.2006.01443.x

DO - 10.1111/j.1442-2042.2006.01443.x

M3 - Article

C2 - 16882058

AN - SCOPUS:33745910846

VL - 13

SP - 932

EP - 938

JO - International Journal of Urology

JF - International Journal of Urology

SN - 0919-8172

IS - 7

ER -